231 related articles for article (PubMed ID: 18440693)
41. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
Baker J; Obermair A; Gebski V; Janda M
Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499
[TBL] [Abstract][Full Text] [Related]
42. ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma
Rodolakis A; Scambia G; Planchamp F; Acien M; Di Spiezio Sardo A; Farrugia M; Grynberg M; Pakiz M; Pavlakis K; Vermeulen N; Zannoni G; Zapardiel I; Macklon KLT
Hum Reprod Open; 2023; 2023(1):hoac057. PubMed ID: 36756380
[TBL] [Abstract][Full Text] [Related]
43. Use of clinicopathological factors to predict prognosis of fertility-sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia.
Zhang X; Zhao X; Wang C; Lu S; Wang Y; He Y; Wang J; Shen D
Oncol Lett; 2023 Feb; 25(2):52. PubMed ID: 36644134
[TBL] [Abstract][Full Text] [Related]
44. MIG-6 Is Critical for Progesterone Responsiveness in Human Complex Atypical Hyperplasia and Early-Stage Endometrial Cancer.
Jeong O; Broaddus RR; Lessey BA; Risinger JI; Hunter MI; Kim TH
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498921
[TBL] [Abstract][Full Text] [Related]
45. Endometrial Hyperplasia.
Ring KL; Mills AM; Modesitt SC
Obstet Gynecol; 2022 Dec; 140(6):1061-1075. PubMed ID: 36357974
[TBL] [Abstract][Full Text] [Related]
46. Fertility-preserving treatment in patients with early-stage endometrial cancer: A protocol for systematic review and meta-analysis.
Zhao XL; Du ZQ; Zhang X; Yao Z; Liang YQ; Zhao SF
Medicine (Baltimore); 2021 Dec; 100(48):e27961. PubMed ID: 35049199
[TBL] [Abstract][Full Text] [Related]
47. The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review.
Piatek S; Michalski W; Sobiczewski P; Bidzinski M; Szewczyk G
Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():139-147. PubMed ID: 34214800
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.
Leone Roberti Maggiore U; Martinelli F; Dondi G; Bogani G; Chiappa V; Evangelista MT; Liberale V; Ditto A; Ferrero S; Raspagliesi F
J Gynecol Oncol; 2019 Jul; 30(4):e57. PubMed ID: 31074240
[TBL] [Abstract][Full Text] [Related]
49. Metformin for endometrial hyperplasia.
Clement NS; Oliver TR; Shiwani H; Sanner JR; Mulvaney CA; Atiomo W
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012214. PubMed ID: 29077194
[TBL] [Abstract][Full Text] [Related]
50. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review.
Wei J; Zhang W; Feng L; Gao W
Medicine (Baltimore); 2017 Sep; 96(37):e8034. PubMed ID: 28906392
[TBL] [Abstract][Full Text] [Related]
51. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
[TBL] [Abstract][Full Text] [Related]
52. Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment.
Yang YF; Liao YY; Liu XL; Su SG; Li LZ; Peng NF
Gynecol Oncol; 2015 Dec; 139(3):419-23. PubMed ID: 26494424
[TBL] [Abstract][Full Text] [Related]
53. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
54. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.
Pashov AI; Tskhay VB; Ionouchene SV
Gynecol Endocrinol; 2012 Jul; 28(7):559-61. PubMed ID: 22296608
[TBL] [Abstract][Full Text] [Related]
55. Comparative effects of progestin-based combination therapy for endometrial cancer or atypical endometrial hyperplasia: a systematic review and network meta-analysis.
Cui J; Zhao YC; She LZ; Wang TJ
Front Oncol; 2024; 14():1391546. PubMed ID: 38764577
[TBL] [Abstract][Full Text] [Related]
56. Mirena: Just a contraceptive device? or A modality with diverse clinical applications !
Agarwal N; Chopra S
J Family Med Prim Care; 2022 Sep; 11(9):5031-5037. PubMed ID: 36505540
[TBL] [Abstract][Full Text] [Related]
57. Progesterone Actions and Resistance in Gynecological Disorders.
MacLean JA; Hayashi K
Cells; 2022 Feb; 11(4):. PubMed ID: 35203298
[TBL] [Abstract][Full Text] [Related]
58. Endometrial hyperplasia as a risk factor of endometrial cancer.
Nees LK; Heublein S; Steinmacher S; Juhasz-Böss I; Brucker S; Tempfer CB; Wallwiener M
Arch Gynecol Obstet; 2022 Aug; 306(2):407-421. PubMed ID: 35001185
[TBL] [Abstract][Full Text] [Related]
59. Molecular Classification to Prognosticate Response in Medically Managed Endometrial Cancers and Endometrial Intraepithelial Neoplasia.
Puechl AM; Spinosa D; Berchuck A; Secord AA; Drury KE; Broadwater G; Wong J; Whitaker R; Devos N; Corcoran DL; Strickland KC; Previs RA
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200374
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: Can biomarkers predict response?
Dore M; Filoche S; Danielson K; Henry C
Gynecol Oncol Rep; 2021 May; 36():100732. PubMed ID: 33718563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
